

Summary of Analysis Sets
(All Participants Randomized)

| | Placebo n (%) | Xanomeline line Low Dose n (%) | Xanomeline line High Dose n (%) |
|--|------------------|--------------------------------------|---------------------------------------|
| Participants in Population | 86 | 84 | 84 |
| Participants included in ITT population | 86 (100.0) | 84 (100.0) | 84 (100.0) |
| Participants included in efficacy population | 79 (91.9) | 81 (96.4) | 74 (88.1) |
| Participants included in safety population | 86 (100.0) | 84 (100.0) | 84 (100.0) |